Revenue and Profitability - The company's revenue for Q1 2025 reached ¥309,969,965.34, representing a 106.29% increase compared to ¥150,256,744.79 in the same period last year[5] - Net profit attributable to shareholders was ¥69,868,367.53, a significant turnaround from a loss of ¥14,102,003.37, marking a 595.45% increase[5] - Basic and diluted earnings per share improved to ¥0.08, compared to a loss of ¥0.02 per share in the same period last year, reflecting a 500.00% increase[5] - The net profit for the current period was ¥69,439,025.34, a turnaround from a net loss of ¥14,350,051.02 in the previous period[22] - The profit attributable to the parent company's shareholders was ¥69,868,367.53, compared to a loss of ¥14,102,003.37 in the prior period[23] - The company reported a total comprehensive income of ¥69,339,641.98, recovering from a loss of ¥14,111,841.40 in the previous period[23] Cash Flow - The net cash flow from operating activities was ¥40,425,295.32, up 166.79% from ¥15,152,592.91 in the previous year[5] - Cash flow from operating activities showed a significant improvement, with cash received from sales reaching ¥190,318,882.35, compared to ¥130,536,094.26 in the previous period[25] - The net cash flow from operating activities was $40,425,295.32, an increase from $15,152,592.91 in the previous period, indicating a significant improvement in operational efficiency[26] - Total cash inflow from financing activities was $70,000,000.00, while cash outflow amounted to $120,077,959.58, resulting in a net cash flow of -$50,077,959.58, reflecting a decrease in financing activities[26] - The total cash inflow from investment activities was $3,746,209.90, while cash outflow was $34,282,205.58, leading to a net cash flow of -$30,535,995.68, indicating a substantial investment in assets[26] - The company received $9,311,755.88 in tax refunds, contributing positively to cash inflows from operating activities[26] Assets and Liabilities - The total assets at the end of Q1 2025 were ¥3,038,045,570.70, a slight increase of 0.99% from ¥3,008,225,640.09 at the end of the previous year[5] - Total current assets amount to ¥494,618,808.48, an increase from ¥463,048,006.84 at the beginning of the period[18] - Total liabilities decreased slightly to ¥2,371,659,416.70 from ¥2,411,179,128.07, reflecting a reduction of approximately 1.6%[22] - The company has a total of ¥82,878,785.91 in contract liabilities, down from ¥124,478,071.04, indicating a reduction of approximately 33%[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 57,273[14] - The largest shareholder, Zeng Shaogui, holds 11.16% of shares, amounting to 98,533,635 shares, with 95,732,245 shares pledged[14] - The company is actively involved in financing activities, with a notable shareholder, Tibet Rongrui Investment Co., holding 5,286,600 shares through margin trading[15] Operating Costs and Expenses - The company's operating costs increased by 115.64% to ¥128,088,503.11, mainly due to higher formulation costs[10] - Total operating costs amounted to ¥231,507,233.07, compared to ¥156,147,173.76 in the prior period, indicating an increase of about 48.2%[22] - Cash paid to employees increased to ¥58,222,746.22 from ¥35,535,450.97, reflecting a rise in labor costs[26] Research and Development - The company has ongoing research and development efforts, with development expenditures amounting to ¥142,685,817.52, up from ¥136,673,090.93[18] - Research and development expenses rose to ¥21,707,434.32 from ¥18,999,351.04, an increase of approximately 9.0%[22] Inventory and Accounts Receivable - The increase in accounts receivable was 73.91%, reaching ¥166,562,869.28, primarily due to increased revenue[9] - Accounts receivable increased significantly to ¥166,562,869.28 from ¥95,773,533.23, indicating a growth of approximately 74%[18] - Inventory decreased to ¥225,749,209.48 from ¥238,630,347.88, reflecting a decline of about 5.4%[18] Audit and Reliability - The company did not undergo an audit for the first quarter report, which may affect the reliability of the financial data presented[28]

Financial Performance - The net profit attributable to shareholders of the company significantly reduced losses year-on-year, primarily due to changes in revenue structure and an increase in overseas revenue proportion[7]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a 25% year-over-year growth[21]. - The company's operating revenue for 2024 reached ¥590,199,011.64, representing a 36.82% increase compared to ¥431,384,112.87 in 2023[26]. - The net profit attributable to shareholders improved to -¥173,654,017.08 in 2024, a 66.21% reduction in losses from -¥513,876,149.69 in 2023[26]. - The net cash flow from operating activities surged to ¥164,705,660.55, a significant increase of 4,757.21% compared to -¥3,536,573.51 in 2023[26]. - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was -¥239,652,787.96 in 2024, a 59.44% improvement from -¥590,913,670.38 in 2023[26]. - The basic and diluted earnings per share improved to -¥0.20 in 2024, a 65.52% increase from -¥0.58 in 2023[26]. - The company's weighted average return on equity improved to -26.02% in 2024, up 24.62% from -50.64% in 2023[26]. Revenue Growth and Market Expansion - The overseas sales of peptide formulations and active pharmaceutical ingredients continued to grow, driving overall revenue growth for the company[7]. - The report indicates a substantial increase in overseas business, contributing to the overall revenue growth[7]. - The company is expanding its market presence in Europe, targeting a 20% increase in market share by the end of the fiscal year[21]. - The international business accounted for over 50% of total revenue, with overseas sales of liraglutide formulations and GLP-1 raw materials significantly contributing to growth, achieving a 189.79% increase in foreign revenue[76][78]. - The company plans to accelerate its global strategy in peptide and small nucleic acid formulations, as well as API and CDMO/CMO businesses, targeting markets in North America, South America, Europe, Asia, and the Middle East[38]. Research and Development - New product development includes a novel nasal spray for COVID-19, developed in collaboration with the Chinese Academy of Sciences[20]. - Clinical trials for the new GLP-1 receptor agonist are progressing, with Phase III trials expected to start in Q2 2024[20]. - The company aims to enhance its R&D efficiency and product competitiveness by integrating cutting-edge technologies such as biotechnology and artificial intelligence into its processes[38]. - The company is focused on expanding its research and development capabilities, particularly in peptide drug development, with over 15 years of experience in the field[159]. - The company is advancing multiple products towards market approval, including HY3000 and HY3001, which are in clinical trials aimed at obtaining Chinese market licenses[96]. Operational Efficiency and Cost Management - The company aims to reduce operational costs by 10% through improved supply chain management strategies[21]. - The company is investing 100 million RMB in new technology for drug manufacturing to improve efficiency and reduce costs[21]. - The management team has implemented refined operational processes across the supply chain, enhancing efficiency and service quality[58]. - The company has established a comprehensive quality management system, achieving certifications from multiple international regulatory bodies, including FDA and GMP[57]. Corporate Governance and Compliance - The company emphasizes strict quality control throughout the drug production process to mitigate risks related to product quality[129]. - The company has established a value management system to enhance transparency and align market value with intrinsic value[133]. - The company has established a transparent performance evaluation and incentive mechanism for directors, supervisors, and senior management, ensuring compliance with relevant laws and regulations[143]. - The company strictly adheres to legal requirements for information disclosure, ensuring timely and accurate communication with shareholders through designated media[144]. - The company maintains a clear separation of assets, personnel, finance, institutions, and business from its controlling shareholder, ensuring independent operations[148]. Shareholder Engagement and Social Responsibility - The company has committed to social responsibility initiatives, including poverty alleviation and ecological protection, while ensuring shareholder interests[146]. - The company ensures equal treatment of all shareholders, particularly minority shareholders, allowing them to fully exercise their rights[138]. - The company actively communicates with investors through various channels, enhancing understanding and recognition among stakeholders[145]. Future Outlook and Strategic Goals - Future development strategies and plans are outlined in the management discussion and analysis section, emphasizing the need for investors to recognize associated risks[7]. - The company anticipates 2025 to be a pivotal year for growth, driven by optimized product structure and improved operational efficiency[124]. - The company plans to enhance its international strategy by expanding overseas marketing, accelerating product registration, and strengthening global partnerships[122]. - The company is committed to addressing potential risks in drug innovation and development, ensuring a robust pipeline of products[126]. Internal Control and Risk Management - The company has established a strict internal control system to manage risks and ensure compliance, enhancing the internal audit function[190]. - The company has not reported any significant internal control deficiencies during the reporting period[191]. - The supervisory board found no significant risks during its oversight activities in the reporting period[179]. - Measures are in place to prevent core technology leakage, including confidentiality agreements and enhanced information security systems[128].

二、董事会专门委员会履职情况 深圳翰宇药业股份有限公司 2024年度独立董事述职报告 （钟廉） 本人作为深圳翰宇药业股份有限公司（以下简称"公司"）的独立董事，在 2024年任职期间严格按照《中华人民共和国公司法》《中华人民共和国证券法》 《关于在上市公司建立独立董事制度的指导意见》《深圳翰宇药业股份有限公司 公司章程》（以下简称"《公司章程》"）《深圳翰宇药业股份有限公司独立董事 工作制度》等相关法律、法规、规章的规定和要求，做到诚实、勤勉、独立的履 行职责，积极出席相关会议，认真审议董事会各项议案，对公司重大事项发表了 独立意见，较好地发挥了独立董事及专业委员的作用。现就本人2024年度履行独 立董事职责情况述职如下： 一、出席会议情况 本着勤勉尽责的态度，我积极参加公司召开的董事会和股东大会。报告期内， 共参与了9次董事会会议，未出现连续两次未亲自出席会议的情形。在审议董事 会各项议案过程中，我坚持独立、审慎的判断原则，结合自身专业知识和对公司 实际情况的了解，认真履行表决权。在审议过程中对相关议案提出了意见和建议， 并根据具体情况发表了相应独立意见。在我看来，报告期内公司董事会和股东大 会的召集和召开 ...

深圳翰宇药业股份有限公司 关联交易管理制度 第一章 总则 第一条 为规范深圳翰宇药业股份有限公司（以下简称"公司"或"本公司"） 关联交易的决策管理和信息披露等事项，确保公司的关联交易行为不损害公司和全 体股东特别是无关联关系股东的利益，根据《中华人民共和国公司法》、《中华人 民共和国证券法》、《企业会计准则》、《深圳证券交易所创业板股票上市规则》 （以下简称"《创业板股票上市规则》"）及其他有关法律法规、规范性文件和《公 司章程》的规定，结合公司实际情况，特制定本制度。 （一）直接或间接地控制公司的法人或其他组织； 第二条 公司关联交易的决策管理、信息披露等事项，应当遵守本制度。 第三条 公司处理关联交易事项，应当遵循下列原则： （一）诚实信用的原则； （二）公开、公平、公正的原则； （三）依据客观标准判断的原则； （四）实质重于形式的原则。 第二章 关联人和关联关系 第四条 公司关联人包括关联法人和关联自然人。 第五条 具有下列情形之一的法人或其他组织，为本公司的关联法人： （二）由前项所述法人直接或间接控制的除本公司及其控股子公司以外的法人 或其他组织； （三）由第六条所列本公司的关联自然人直接或间接控 ...

深圳翰宇药业股份有限公司 2024年度独立董事述职报告 （许立勇） 本人作为深圳翰宇药业股份有限公司（以下简称"公司"）的独立董事，在2024 年任职期间严格按照《中华人民共和国公司法》《中华人民共和国证券法》《关 于在上市公司建立独立董事制度的指导意见》《深圳翰宇药业股份有限公司公司 章程》（以下简称"《公司章程》"）《深圳翰宇药业股份有限公司独立董事工作 制度》等相关法律、法规、规章的规定和要求，做到诚实、勤勉、独立的履行职 责，积极出席相关会议，认真审议董事会各项议案，对公司重大事项发表了独立 意见，较好地发挥了独立董事及专业委员的作用。现就本人2024年度履行独立董 事职责情况述职如下： 一、出席会议情况 本人于 2024 年度新任公司独立董事，因任职时间尚短，自受聘至 2024 年 12 月 31 日期间，公司尚未召开董事会会议或相关专门委员会会议，因此本人在 该期间未参与相关议案的审议表决。 尽管如此，任职以来本人始终高度重视独立董事职责，始终秉持勤勉尽责、 独立公正的原则，积极主动履职。在任期内，我多次到访公司，深入了解企业运 作实际情况，主动与公司董事会成员及管理层开展深入沟通，就公司经营状况 ...

深圳翰宇药业股份有限公司 董事会关于独立董事独立性情况的专项意见 根据《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指 引第2号——创业板上市公司规范运作》等要求，深圳翰宇药业股份有限公司（以 下简称"公司"或"翰宇药业"）董事会就公司在任独立董事胡文言、康志红、 许立勇的独立性情况进行评估并出具如下专项意见： 经核查独立董事胡文言、康志红、许立勇的任职经历以及签署的相关自查文 件，2024年度上述人员未在公司担任除独立董事以外的任何职务，也未在公司主 要股东担任任何职务，与公司以及主要股东之间不存在利害关系或可能影响其独 立客观判断的情形。公司董事会认为公司独立董事符合《上市公司独立董事管理 办法》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范 运作》中关于独立董事的任职资格及独立性的要求。 深圳翰宇药业股份有限公司董事会 2025年4月26日 ...

2024年度独立董事述职报告 深圳翰宇药业股份有限公司 （胡文言） 根据《中华人民共和国公司法》《中华人民共和国证券法》《关于在上市公 司建立独立董事制度的指导意见》《深圳翰宇药业股份有限公司（以下简称"公 司"）章程》（以下简称"《公司章程》"）《深圳翰宇药业股份有限公司独立董 事工作制度》等相关法律、法规、规章的规定和要求，作为公司独立董事，本人 诚实、勤勉、独立的履行职责，积极出席相关会议，认真审议董事会各项议案， 对公司重大事项发表了独立意见，较好地发挥了独立董事及专业委员的作用。现 就本人2024年度履行独立董事职责情况述职如下： 一、年度履职情况 2024年，本人积极参加公司股东大会、董事会、独立董事专门会议及任职的 专门委员会，对所有需要审议的各项会议议案和相关材料均提前进行了详细阅读， 在审议议案时独立发表意见，依法表决，为会议正确、科学地决策发挥积极作用。 具体履职情况如下： （一）董事会、股东大会履职情况 2024年任职期间，本人均亲自出席全部董事会，未发生连续两次未亲自出席 会议，或任职期间内连续十二个月未亲自出席董事会会议超过期间董事会总数的 二分之一的情形。本人认为，2024年度公司 ...

深圳翰宇药业股份有限公司 总裁工作细则 第一章 总则 第一条 为更好的管理深圳翰宇药业股份有限公司（以下简称"公司"）生产 经营工作，促进公司经营管理的制度化、规范化、科学化，确保公司重大生产经 营决策的正确性、合理性，提高民主决策、科学决策水平，以使公司的生产经营 高效有序进行，根据《中华人民共和国公司法》、《深圳翰宇药业股份有限公司章 程》（以下简称"《公司章程》"）有关规定，并结合公司的实际情况，制定《深圳 翰宇药业股份有限公司总裁工作细则》（以下简称"本细则"）。 第二条 公司设总裁一名，由公司董事长提名，董事会聘任或解聘；公司设 执行总裁一名、副总裁若干名，由总裁提名，董事会聘任或解聘。 第三条 公司总裁主持公司日常业务经营和管理工作，并受董事会委托组织 实施董事会会议决议，对董事会负责。 第四条 本细则所称总裁是指总裁本人或经合法授权以总裁名义对外行使其 权限的副总裁等高级管理人员。 第五条 总裁的工作应贯彻诚信、勤勉、守法、高效的原则。 第二章 总裁职责、权限 第六条 总裁按照《公司章程》的规定全面主持公司经营管理事务，并向董 事会负责。 第七条 总裁享有的职权如下： 1 （一）主持公司的生产经 ...

3、《关于作废 2022 年限制性股票激励计划部分已授予但尚未归属的限制性 股票》的审核意见 深圳翰宇药业股份有限公司 第六届董事会第一次独立董事专门会议审核意见 根据《中华人民共和国公司法》《中华人民共和国证券法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》《公司章程》以及《独立董事制度》等相关法律法规、 规章制度的有关规定，我们作为公司的独立董事，基于独立判断的立场，本着实 事求是的原则，召开了第六届董事会第一次独立董事专门会议，独立董事认真审 阅了议案内容，在保证所获得的资料真实、准确、完整的基础上，本着勤勉尽责 的态度，基于独立客观的原则并发表审核意见如下： 1、《关于公司 2024 年度利润分配预案的议案》的审核意见 经审核，我们认为：《关于公司 2024 年度利润分配预案的议案》符合《公 司法》《关于进一步落实上市公司现金分红有关事项的通知》《上市公司监管指 引第 3 号——上市公司现金分红》及《公司章程》等相关规定，有利于公司的持 续稳定健康发展，不存在损害股东尤其是中小股东利益的情况。同意本次董事会 提出的《关于公司 202 ...

深圳翰宇药业股份有限公司 独立董事述职报告（康志红） 本人作为深圳翰宇药业股份有限公司（以下简称"公司"或"翰宇药业"） 的独立董事，在2024年任职期间严格按照《中华人民共和国公司法》《中华人民 共和国证券法》《关于在上市公司建立独立董事制度的指导意见》《深圳翰宇药 业股份有限公司公司章程》（以下简称"《公司章程》"）《深圳翰宇药业股份有 限公司独立董事工作制度》等相关法律、法规、规章的规定和要求，做到诚实、 勤勉、独立的履行职责，积极出席相关会议，认真审议董事会各项议案，对公司 重大事项发表了独立意见，较好地发挥了独立董事及专业委员会的作用。现就本 人2024年度履行独立董事职责情况述职如下： 一、2024年度履职概况 2024年，本人积极参加公司股东大会、董事会、独立董事专门会议及任职的 专门委员会，对所有需要审议的各项会议议案和相关材料均提前进行了详细阅读， 在审议议案时独立发表意见，依法表决，为会议正确、科学地决策发挥积极作用。 具体履职情况如下： （一）董事会、股东大会履职情况 在2024年度任职期间，本人共计参加公司董事会会议10次，其中通过线上形 式参加2次，现场参加8次；此外，出席股东大会3 ...